Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $231,604.48 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 7,867 shares of Castle Biosciences stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $29.44, for a total value of $231,604.48. Following the completion of the sale, the director now directly owns 5,700 shares in the company, valued at $167,808. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Daniel Bradbury also recently made the following trade(s):

• On Monday, August 12th, Daniel Bradbury sold 7,883 shares of Castle Biosciences stock. The shares were sold at an average price of $26.65, for a total transaction of $210,081.95.

Castle Biosciences Trading Up 10.6 %

Shares of NASDAQ:CSTL opened at $31.31 on Friday. The company has a 50-day simple moving average of $28.74 and a 200 day simple moving average of $24.16. The company has a market capitalization of $864.47 million, a P/E ratio of -223.64 and a beta of 1.03. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.92 and a current ratio of 8.12. Castle Biosciences, Inc. has a 52-week low of $12.07 and a 52-week high of $32.53.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Monday, August 5th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.47. Castle Biosciences had a negative return on equity of 0.77% and a negative net margin of 1.08%. The business had revenue of $87.00 million for the quarter, compared to analyst estimates of $69.95 million. During the same period in the previous year, the firm earned ($0.70) EPS. Sell-side analysts forecast that Castle Biosciences, Inc. will post -0.58 earnings per share for the current year.

Institutional Trading of Castle Biosciences

A number of hedge funds have recently modified their holdings of CSTL. Parkman Healthcare Partners LLC raised its holdings in Castle Biosciences by 59.0% in the 4th quarter. Parkman Healthcare Partners LLC now owns 357,156 shares of the company’s stock valued at $7,707,000 after acquiring an additional 132,564 shares during the period. Acadian Asset Management LLC lifted its holdings in Castle Biosciences by 130.7% during the 1st quarter. Acadian Asset Management LLC now owns 210,824 shares of the company’s stock worth $4,669,000 after purchasing an additional 119,443 shares during the last quarter. Marshall Wace LLP boosted its stake in Castle Biosciences by 116.5% in the 2nd quarter. Marshall Wace LLP now owns 212,036 shares of the company’s stock valued at $4,616,000 after purchasing an additional 114,104 shares during the period. Harbor Capital Advisors Inc. grew its holdings in Castle Biosciences by 249.3% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock valued at $3,020,000 after buying an additional 99,001 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Castle Biosciences by 47.3% during the 2nd quarter. Renaissance Technologies LLC now owns 301,500 shares of the company’s stock worth $6,564,000 after buying an additional 96,800 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

CSTL has been the subject of several analyst reports. Robert W. Baird raised their price objective on Castle Biosciences from $34.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, August 6th. Stephens reaffirmed an “overweight” rating and set a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, August 6th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $32.80.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.